This session will involve a clinical trials update and state of the art management in bronchiectasis and NTM. New guidelines for NTM, as well as recently FDA approved therapies, such as inhaled liposomal amikacin have been developed and will be discussed. Therapies that have received FDA breakthrough status, including brensocatib, an inhibitor of dipeptidyl peptidase 1, will be discussed. Other therapies including inhaled colistin and phage therapy show promise in the treatment of bronchiectasis and NTM and will be presented. The rapidly evolving care of the bronchiectasis patient in the digital era and telehealth will also be discussed. Finally, a panel discussion involving questions and answers with the speakers will conclude the session.
CME credits and/or Certificates of Completion are not provided for this session.
1- Discuss new treatment options, including inhaled liposomal amikacin and others, as described in recently published guidelines
2- Describe how to care for the bronchiectasis patient in the rapidly evolving digital and telehealth arena
Julie Philley, MD: Digital Health and Caring for the Bronchiectasis Patient
Kevin L. Winthrop, MD, MPH: Two vs. Three Antibiotics For MAC
Kenneth N. Oliver, MD, MPH, ATSF: Inhaled Therapies: Liposomal Amikacin, Colistin, and Others
James D. Chalmers, MD, PhD: Inhibitors of Neutrophil-Mediated Inflammation in Bronchiectasis
Paul Turner, PhD: Phage Therapy for NTM and Other Resistant Organisms
Ashwin Basavaraj, MD, FCCP, ATSF: panel discussion
You can save 20% today by joining the ATS. Join more than 16,000 healthcare providers and researchers as a member of the American Thoracic Society today. As an ATS member, you’ll gain access to cutting-edge science, collaboration opportunities, discounts on the annual ATS International Conference, and resources to share with patients. The ATS offers multiple ways to get involved, from Assembly membership to in-person networking opportunities, as well as an online community offered through DocMatter. Join the ATS Today!